2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- PMID: 35363499
- DOI: 10.1161/CIR.0000000000001063
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Erratum in
-
Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022 May 3;145(18):e1033. doi: 10.1161/CIR.0000000000001073. Epub 2022 May 2. Circulation. 2022. PMID: 35500054 No abstract available.
-
Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022 Sep 27;146(13):e185. doi: 10.1161/CIR.0000000000001097. Epub 2022 Sep 26. Circulation. 2022. PMID: 36154623 No abstract available.
-
Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2023 Apr 4;147(14):e674. doi: 10.1161/CIR.0000000000001142. Epub 2023 Apr 3. Circulation. 2023. PMID: 37011077 No abstract available.
Abstract
Aim: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
Methods: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.
Keywords: ACE inhibitors; AHA Scientific Statements; SGLT2 inhibitors; acute decompensated heart failure; angiotensin and neprilysin receptor antagonist; angiotensin receptor antagonist; atrial fibrillation; beta blockers; cardiac amyloidosis; cardiac failure; cardio-oncology; cardiogenic shock; cardiomyopathy; cardiomyopathy in pregnancy; chronic heart failure; congestive heart failure; diabetes; guideline-directed medical therapy; heart failure; heart failure rehabilitation; heart failure with mildly reduced ejection fraction; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; mineralocorticoid receptor antagonists; mitral regurgitation; palliative care; reduced ejection fraction; right heart pressure; sacubitril valsartan; social determinants of health; sodium glucose co-transporter 2; systolic heart failure; valvular heart disease.
Comment in
-
Management of Heart Failure: Updated Guidelines From the AHA/ACC.Am Fam Physician. 2023 Sep;108(3):315-320. Am Fam Physician. 2023. PMID: 37725476 No abstract available.
Similar articles
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022 May 3;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062. Epub 2022 Apr 1. Circulation. 2022. PMID: 35363500 Review.
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1. J Am Coll Cardiol. 2022. PMID: 35379503
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2022 May 3;79(17):1757-1780. doi: 10.1016/j.jacc.2021.12.011. Epub 2022 Apr 1. J Am Coll Cardiol. 2022. PMID: 35379504
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.J Card Fail. 2022 May;28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010. Epub 2022 Apr 1. J Card Fail. 2022. PMID: 35378257
-
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.J Card Fail. 2017 Aug;23(8):628-651. doi: 10.1016/j.cardfail.2017.04.014. Epub 2017 Apr 28. J Card Fail. 2017. PMID: 28461259 Review. No abstract available.
Cited by
-
The prescription of beta-blockers in older patients with heart failure with reduced ejection fraction: an observational study in Vietnam.Sci Rep. 2024 Jun 5;14(1):12923. doi: 10.1038/s41598-024-63479-w. Sci Rep. 2024. PMID: 38839862 Free PMC article.
-
Examining health-related quality of life in ambulatory adult patients with chronic heart failure: insights from Malaysia using EQ-5D-5L.Qual Life Res. 2024 Jun 5. doi: 10.1007/s11136-024-03674-4. Online ahead of print. Qual Life Res. 2024. PMID: 38839679
-
Blood pressure and heart failure: focused on treatment.Clin Hypertens. 2024 Jun 1;30(1):15. doi: 10.1186/s40885-024-00271-y. Clin Hypertens. 2024. PMID: 38822445 Free PMC article. Review.
-
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives.World J Cardiol. 2024 May 26;16(5):240-259. doi: 10.4330/wjc.v16.i5.240. World J Cardiol. 2024. PMID: 38817648 Free PMC article. Review.
-
Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.BMC Cardiovasc Disord. 2024 May 30;24(1):285. doi: 10.1186/s12872-024-03961-5. BMC Cardiovasc Disord. 2024. PMID: 38816795 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous